Hikma has approached GlaxoSmithKline to potentially acquire certain GSK businesses in Egypt and Tunisia.
The London-based generics and injectables player has entered a non-binding term sheet for the Pharmaceutical and Consumer Health business in...
Hikma Opens Discussions To Acquire GSK Businesses In Egypt And Tunisia
Deal Would Include Hikma Acquiring GSK’s 91.2% Holding
Listen to this article
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
Stay ahead of every shift in generics and biosimilars.
More from Deals
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
More from Business
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains